The Bronx, NYNCT06308588Now EnrollingIRB Ready

Philadelphia Chromosome-Positive Clinical Trial in The Bronx, NY

Access cutting-edge philadelphia chromosome-positive treatment through this phase 1/2 clinical trial at a research site in The Bronx. Study-provided care at no cost to qualified participants.

Sponsored by M.D. Anderson Cancer Center

Quick Self-Assessment

See if you qualify for this The Bronx location

Preparing your pre-screening questions…

Expert Care in The Bronx

Access philadelphia chromosome-positive specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related philadelphia chromosome-positive treatment provided free

Apply for This The Bronx Location

Check if you qualify for this philadelphia chromosome-positive clinical trial in The Bronx, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to The Bronx

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit The Bronx site if eligible
  4. 4Begin participation

About This Philadelphia Chromosome-Positive Study in The Bronx

To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.

Sponsor: M.D. Anderson Cancer Center

Who Can Participate

Inclusion Criteria

Diagnosis of one of the following: a) Participants ≥18 years of age with previously untreated or minimally pretreated Ph-positive ALL who are not suitable candidates for intensive chemotherapy. Participants who have received no more than one or two courses of chemotherapy with or without other TKIs are considered minimally pretreated and still eligible if they have persistently detectable MRD. i. If they are in morphologic remission at enrollment, they are evaluable only MRD responses, RFS and OS b) Participants ≥ 12 years of age with relapsed/refractory Ph-positive ALL or with previously treated lymphoid blast phase CML
Performance status ≤2 (ECOG Scale) if age ≥18 years or Lansky ≥50 if age \<18 years
Weight ≥40kg
Adequate liver function as defined by the following criteria (unless the increased values are judged to be leukemia disease related):
Total serum bilirubin ≤ 2 x upper limit of normal (ULN), unless due to Gilbert's syndrome
Alanine aminotransferase (ALT) ≤ 3 x ULN, OR
Aspartate aminotransferase (AST) ≤ 3 x ULN
Adequate renal function defined as: a) Creatinine clearance ≥30 mL/min
Adequate pancreatic function as defined by the following criteria: a) Serum lipase and amylase \< 1.5 x ULN
Adequate cardiac function as assessed clinically by history and physical examination.
For females of childbearing potential, a negative urine pregnancy test must be documented
Willingness to use adequate contraception prior to study entry, for the duration of study participation, and for 4 months after completion of study participation. For women of child-bearing potential, adequate methods of contraception include: complete abstinence, hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device (IUD), tubal Ligation or hysterectomy, subject/partner post vasectomy, implantable or injectable contraceptives, and condoms plus spermicide
Ability to understand and the willingness to sign a written informed consent document.
Signed informed consent

Exclusion Criteria

Active serious infection not controlled by oral or intravenous antibiotics.
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than 1 year.
Active Grade III-V cardiac failure as defined by the New York Heart Association Criteria.
Prolonged QTc interval on pre-entry electrocardiogram (\> 470 msec) unless corrected after electrolyte replacement or approved by cardiologist
History or presence of clinically relevant CNS pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. (Participants with active CNS leukemia will NOT be excluded)
Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator. Cytarabine 2 g/m2 (or alternative) for cytoreduction is permitted.
Pregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in The Bronx?

Yes, this clinical trial (NCT06308588) has an active research site in The Bronx, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Philadelphia Chromosome-Positive Treatment Options in The Bronx, NY

If you're searching for philadelphia chromosome-positive treatment options in The Bronx, NY, this clinical trial (NCT06308588) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our The Bronx research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced philadelphia chromosome-positive specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all philadelphia chromosome-positive clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in The Bronx, NY

See all alzheimers disease clinical trials recruiting in The Bronx — not just this study.

Browse Alzheimers Disease Trials in The Bronx →

Browse More Trials by Condition

Alzheimers Disease TrialsPulmonary Hypertension TrialsAtopic Dermatitis TrialsChronic Myeloid Leukemia TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in The Bronx?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · The Bronx, NY